Associated Genetic Biomarkers
EWSR1-FLI1 Fusion is present in 0.23% of AACR GENIE cases, with Ewing sarcoma, sarcoma, NOS, soft tissue neoplasm, unknown, and breast invasive ductal carcinoma having the greatest prevalence .
EWSR1-FLI1 Fusion serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain EWSR1-FLI1 Fusion as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with EWSR1-FLI1 Fusion in the inclusion eligibility criteria most commonly target Ewing sarcoma .
Irinotecan, busulfan, celecoxib, cyclophosphamide, and doxorubicin are the most frequent therapies in trials with EWSR1-FLI1 Fusion as an inclusion criteria .
Significance of EWSR1-FLI1 Fusion in Diseases
Ewing Sarcoma +
EWSR1-FLI1 Fusion is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain EWSR1-FLI1 Fusion and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.